Innovative drugs to treat depression: Did animal models fail to be predictive or did clinical trials fail to detect effects

Neuropsychopharmacology

Volumn 39, Issue 5, 2014, Pages 1041-1051

  Belzung, Catherine ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

animal models; antidepressants; depression; treatments; validity

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PHENELZINE; SAREDUTANT;

CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; DEPRESSION; HUMAN; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DISEASE MODEL; DRUG DEVELOPMENT; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84896390001     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.342     Document Type: Review

References (122)

1. Abramson LY, Seligman MEP (1977). Modeling psychopathology in the laboratory: history and rationale. In: Maser JD, Seligman MEP (eds). Psychopathology: Experimental Models. WH Freeman: San Francisco, pp 1-26.
2. Anisman H, Ravindran AV, Griffiths J, Merali Z (1999). Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 4: 182-188. (Pubitemid 29163982)
3. Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW et al (2011). A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 72: 1405-1012.
4. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF et al (2000). Genealogies of mouse inbred strains. Nat Genet 24: 23-25. (Pubitemid 30041415)
5. Belzung C, Philippot P (2007). Anxiety from a phylogenetic perspective: Is there a qualitative difference between human and animal anxiety? Neural Plast 2007: 59676.
6. Belzung C, Lemoine M (2011). Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord 1: 9.
7. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868. (Pubitemid 43228853)
8. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA et al (2009). The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 14: 764-773.
9. Blondeau N, Nguemeni C, Debruyne DN, Piens M, Wu X, Pan H et al (2009). Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology 34: 2548-2559.
10. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ et al (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30: 1131-1152. (Pubitemid 32368013)
11. Bot M, Pouwer F, Assies J, Jansen EH, Diamant M, Snoek FJ et al (2010). Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord 126: 282-286.
12. Breuer ME, van Gaalen MM, Wernet W, Claessens SE, Oosting RS, Behl B et al (2009). SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model. Naunyn Schmiedebergs Arch Pharmacol 379: 101-106.
13. Calatayud F, Belzung C (2001). Emotional reactivity in mice, a case of nongenetic heredity? Physiol Behav 74: 355-362. (Pubitemid 33070410)
14. Calatayud F, Coubard S, Belzung C (2004). Emotional reactivity in mice may not be inherited but influenced by parents. Physiol Behav 80: 465-474. (Pubitemid 38117022)
15. Caldwell J (1981). The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev 12: 221-237. (Pubitemid 12072719)
16. Cheung C, Gonzalez FJ (2008). Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327: 288-299.
17. Cryan JF, Holmes A (2005). The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790. (Pubitemid 43090498)
18. Czéh B, Pudovkina O, van der Hart MG, Simon M, Heilbronner U, Michaelis T et al (2005). Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression. Psychopharmacology (Berl) 180: 548-557. (Pubitemid 40905044)
19. Dableh LJ, Yashpal K, Rochford J, Henry JL (2005). Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507: 99-105. (Pubitemid 40126845)
20. Dalla C, Pitychoutis PM, Kokras N, Papadopoulou-Daifoti Z (2011). Sex differences in response to stress and expression of depressive-like behaviours in the rat. Curr Top Behav Neurosci 8: 97-118.
21. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R et al (2008). Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study ofomega-3 fatty-acid supplementation. J Affect Disord 111: 351-359.
22. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I et al (2009). Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62: 479-493.
23. Dournes C, Beeské S, Belzung C, Griebel G (2013). Deep brain stimulation in treatment-resistant depression in mice: comparison with the CRF1 antagonist, SSR125543. Prog Neuropsychopharmacol Biol Psychiatry 40: 213-220.
24. Ducottet C, Belzung C (2005). Correlations between behaviours in the elevated plus-maze and sensitivity to unpredictable subchronic mild stress: evidence from inbred strains of mice. Behav Brain Res 156: 153-162. (Pubitemid 39330445)
25. Ducottet C, Griebel G, Belzung C (2003). Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 625-631. (Pubitemid 36645063)
26. Dulawa SC, Hen R (2005). Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29: 771-783. (Pubitemid 40762599)
27. Ebner K, Sartori SB, Singewald N (2009). Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 15: 1647-1674.
28. Fernandes C, McKittrick CR, File SE, McEwen BS (1997). Decreased 5-HT1A and increased 5-HT2A receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety. Psychoneuroendocrinology 22: 477-491. (Pubitemid 27505108)
29. Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, Araujo P et al (2011). Chronic o-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressivelike behaviors in rats subjected to a restraint stress protocol. Behav Brain Res 219: 116-122.
30. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC et al (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303: 47-53.
31. Freeman MP, Hibbeln JR, Silver M, Hirschberg AM, Wang B, Yule AM et al (2011). Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause 18: 279-284.
32. Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M et al (2008). Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23: 161-169. (Pubitemid 351308496)
33. Geracioti TD Jr, Loosen PT, Orth DN (1997). Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42: 165-174.
34. Geyer MA, Markou A (1995). Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the Fourth Generation of Progress. Raven Press: New York, pp 787-798.
35. Griebel G, Beeské S (2012). Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol Ther 133: 116-123.
36. Griebel G, Holsboer F (2012). Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov 11: 462-478.
37. Griebel G, Holmes A (2013). 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12: 667-687.
38. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B et al (2002). Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375. (Pubitemid 34493318)
39. Griebel G, Beeské S, Stahl SL (2012). The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 73: 1403-1411.
40. Hasler G, Northoff G (2011). Discovering imaging endophenotypes for major depression. Mol Psychiatry 16: 604-619.
41. Holden C (2005). Sex and the suffering brain. Science 308: 1574.
42. Isingrini E, Camus V, Le Guisquet AM, Pingaud M, Devers S, Belzung C (2010). Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. PLoS One 5: e10404.
43. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM et al (2002). Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust NZ J Psychiatry 36: 384-391. (Pubitemid 34777988)
44. Jutkiewicz EM, Wood SK, Houshyar H, Hsin LW, Rice KC, Woods JH (2005). The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) 180: 215-223. (Pubitemid 40909666)
45. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y et al (2008). ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32: 398-404. (Pubitemid 351178955)
46. Kehne JH, Cain CK (2010). Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stressrelated disorders: evidence from animal models. Pharmacol Ther 128: 460-487.
47. Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J. Clin Psychopharmacol 22: 40-45. (Pubitemid 34101291)
48. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45.
49. Koob GF, Heinrichs SC, Britton K (1998). Animal models of anxiety disorders. In: Schatzberg AF, Nemeroff CB (eds) The American Psychiatric Press Textbook of Psychopharmacology. American Psychiatric Press: Washington DC-London, pp 133-144.
50. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455: 894-902.
51. Lapidus KA, Soleimani L, Murrough JW (2013). Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat 9: 1101-1112.
52. Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR (2011). The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 72: 1054-1062.
53. Lin JH (1998). Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202-1212. (Pubitemid 29028641)
54. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC et al (2011). ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 21: 163-170.
55. Louis C, Cohen C, Depoortère R, Griebel G (2006). Antidepressantlike effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72s schedule in the rat. Neuropsychopharmacology 31: 2180-2187. (Pubitemid 44413195)
56. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (2008). Additional evidence for anxiolytic-and antidepressantlike activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 89: 36-45.
57. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T (2009). Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34: 74-89.
58. Martignoni M, Groothuis GM, de Kanter R (2006). Species differences between mouse, rat, dog, monkey and human CYPmediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2: 875-894. (Pubitemid 44911538)
59. Mathews DC, Henter ID, Zarate CA (2012). Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72: 1313-1333.
60. McArthur R, Borsini F (2006). Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav 84: 436-452. (Pubitemid 44308553)
61. McKinney WT Jr, Bunney WE Jr (1969). Animal model of depression. I: Review of evidence: implications for research. Arch Gen Psychiatry 21: 240-28.
62. Millstein RA, Holmes A (2007). Effects of repeated maternal separation on anxiety-and depression-related phenotypes in different mouse strains. Neurosci Biobehav Rev 31: 3-17. (Pubitemid 44880075)
63. Mineur YS, Prasol DJ, Belzung C, Crusio WE (2003). Agonistic behavior and unpredictable chronic mild stress in mice. Behav Genet 33: 513-519. (Pubitemid 37243297)
64. Mineur YS, Picciotto MR, Sanacora G (2007). Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 61: 250-252. (Pubitemid 46072785)
65. Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE (1992). Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 2: 43-49.
66. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM et al (2011). CYP2C19 variation and citalopram response. Pharmacogenet Genomics 21: 1-9.
67. Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D et al (2012). Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol 26: 1525-1539.
68. Naveen S, Siddalingaswamy M, Singsit D, Khanum F (2013). Antidepressive effect of polyphenols and omega-3 fatty acid from pomegranate peel and flax seed in mice exposed to chronic mild stress. Psychiatry Clin Neurosci 67: 501-508.
69. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14: 1-18. (Pubitemid 38183957)
70. Nguyen QT, Jukic D, Chretien L, Gobeil F, Boussougou M, Regoli D (1994). Two NK-3 receptor subtypes: Demonstration by biological and binding assays. Neuropeptides 27: 157-161. (Pubitemid 24272126)
71. Nielsen DM, Carey GJ, Gold LH (2004). Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499: 135-146. (Pubitemid 39201220)
72. Nollet M, Le Guisquet AM, Belzung C (2013). Models of depression: unpredictable chronic mild stress in mice. Curr Protoc Pharmacol Chapter 5: Unit 5.65.
73. O'Leary OF, Zandy S, Dinan TG, Cryan JF (2013). Lithium augmentation of the effects of desipramine in a mouse model of treatment-resistant depression: a role for hippocampal cell proliferation. Neuroscience 228: 36-46.
74. Overmier JB, Seligman ME (1967). Effects of inescapable shock upon subsequent escape and avoidance responding. J Comp Physiol Psychol 63: 28-33.
75. Overstreet DH (2012). Modeling depression in animal models. Methods Mol Biol 829: 125-144.
76. Overstreet DH, Griebel G (2004). Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497: 49-53. (Pubitemid 39092427)
77. Overstreet DH, Griebel G (2005). Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 82: 223-227. (Pubitemid 41423507)
78. Papp M, Vassout A, Gentsch C (2000). The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 115: 19-23.
79. Pereira AM, Tiemensma J, Romijn JA (2010). Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 92(Suppl 1): 65-70.
80. Philbert J, Belzung C, Griebel G (2013). The CRF(1) receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine. Psychopharmacology 228: 97-107.
81. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391.
82. Pothion S, Bizot JC, Trovero F, Belzung C (2004). Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res 155: 135-146. (Pubitemid 39119974)
83. Quitkin FM, Mcgrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E et al (1989). Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 46: 787-793. (Pubitemid 19233227)
84. Regoli D, Boudon A, Fauchere JL (1994). Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46: 551-599.
85. Riesenberg R, Rosenthal J, Moldauer L, Peterson C (2012). Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxins) in subjects with major depressive disorder. Psychopharmacology (Berl) 221: 601-610.
86. Rupniak NMJ (2003). Animal models of depression: challenges from drug development. Behav Pharmacol 14: 385-390. (Pubitemid 37176797)
87. Salomé N, Stemmelin J, Cohen C, Griebel G (2006). Selective blockade of NK2 or NK3 receptors produces anxiolytic-and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 83: 533-539. (Pubitemid 43817123)
88. Sandi C, Cordero MI, Ugolini A, Varea E, Caberlotto L, Large CH (2008). Chronic stress-induced alterations in amygdala responsiveness and behavior-modulation by trait anxiety and corticotropin-releasing factor systems. Eur J Neurosci 28: 1836-1848.
89. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809. (Pubitemid 36962615)
90. Santos MA, Rocha FL, Hara C (2008). Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 10: 187-190. (Pubitemid 351879952)
91. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr (2010). ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 20: 467-475.
92. Sarter M, Bruno JP (2002). Animal models in Biological psychiatry.. In: D'Haenen HAH, den Boer JA, Willner P (eds) Biological Psychiatry Vol. 1 (Wiley: Chicester, pp 37-44.
93. Shen HW, Yu AM (2009). Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice. Drug Metab Lett 3: 234-241.
94. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S et al (2009). A molecular signature of depression in the amygdala. Am J Psychiatry 166: 1011-1024.
95. Singh AB, Bousman CA, Ng CH, Byron K, Berk M (2012). ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry 2: e198.
96. Soubrié P, Simon P (1989). Les modèles animaux en psychopharmacologie. Confrontations psychiatriques 30: 113-129.
97. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F et al (2001). Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299: 449-458. (Pubitemid 32979655)
98. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85: 367-370. (Pubitemid 15123115)
99. Stewart JW, Garfinkel R, Nunes EV, Donovan S, Klein DF (1998). Atypical features and treatment response in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Clin Psychopharmacol 18: 429-434. (Pubitemid 28555324)
100. Suman-Chauhan N, Grimson P, Guard S, Madden Z, Chung FZ, Watling K et al (1994). Characterisation of [125I][MePhe7]neurokinin B binding to tachykinin NK3 receptors: evidence for interspecies variance. Eur J Pharmacol 269: 65-72.
101. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G et al (2008). Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 64: 293-301.
102. Surget A, Wang W, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G et al (2009). Corticolimbic transcriptome changes are statedependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychoparmacology 34: 1363-1380.
103. Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C et al (2011). Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry 16: 1177-1188.
104. Tanti A, Belzung C (2010). Open questions in current models of antidepressant action. Br J Pharmacol 159: 1187-1200.
105. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
106. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M et al (2008). Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57: 203-209.
107. van der Hart MG, de Biurrun G, Czéh B, Rupniak NM, den Boer JA, Fuchs E (2005). Chronic psychosocial stress in tree shrews: effect of the substance P (NK1 receptor) antagonist L-760735 and clomipramine on endocrine and behavioral parameters. Psychopharmacology (Berl) 181: 207-216. (Pubitemid 41492190)
108. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, Beekman AT et al (2008). Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, doubleblind, placebo-controlled trial. Am J Clin Nutr 88: 706-713.
109. Vancassel S, Leman S, Hanonick L, Denis S, Roger J, Nollet M et al (2008). n-3 Polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J Lipid Res 49: 340-348. (Pubitemid 351213618)
110. Varty GB, Cohen-Williams ME, Hunter JC (2003). The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 14: 87-95. (Pubitemid 36279029)
111. Veenit V, Cordero MI, Tzanoulinou S, Sandi C (2013). Increased corticosterone in peripubertal rats leads to long-lasting alterations in social exploration and aggression. Front Behav Neurosci 7: 26.
112. Venna VR, Deplanque D, Allet C, Belarbi K, Hamdane M, Bordet R (2009). PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology 34: 199-211.
113. Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF (2008). Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. Neuropsychopharmacology 33: 1919-1928. (Pubitemid 351832600)
114. Weiss JM, Kilts CD (1998). Animals models of depression and schizophrenia. In: Schatzberg AF, Nemeroff CB (eds) The American Psychiatric Press Textbook of Psychopharmacology. American Psychiatric Press: Washington DC-London, pp 89-131.
115. Willner P (1984). The validity of animal models of depression. Psychopharmacology 83: 1-16. (Pubitemid 14141479)
116. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987). Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93: 358-364. (Pubitemid 17160661)
117. Willner P, Muscat R, Papp M (1992). Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16: 525-534.
118. Willner P, Scheel-Krüger J, Belzung C (2012). The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev 37: 2331-2371.
119. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P et al (2000). Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 97: 325-330. (Pubitemid 30055830)
120. Wood SK, McFadden KV, Grigoriadis D, Bhatnagar S, Valentino RJ (2012). Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropinreleasing factor. Psychopharmacology (Berl) 222: 325-336.
121. World Health Organization (2008): The Global Burden of Disease 2004 update http://www.who.int/healthinfo/global-burden-disease/GBD-report- 2004update-full.pdf.
122. Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF et al (2006). Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 26: 367-372. (Pubitemid 44192092)